Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Naud

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
European Journal of Gynaecological Oncology|March 24, 2012
Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression modelsK Syrjänen, I Shabalova, L Sarian, et al.
International Journal of STD & AIDS|May 17, 2011
Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3K Syrjänen, I Shabalova, P Naud, et al.
Journal of Medical Screening|September 15, 2005
Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) studyL O Sarian, S F Derchain, P Naud, et al.
Journal of Medical Screening|June 25, 2008
Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS studyS F Derchain, L O Sarian, P Naud, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
European Journal of Gynaecological Oncology|March 24, 2012
Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression modelsK Syrjänen, I Shabalova, L Sarian, et al.
International Journal of STD & AIDS|May 17, 2011
Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3K Syrjänen, I Shabalova, P Naud, et al.
Journal of Medical Screening|September 15, 2005
Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) studyL O Sarian, S F Derchain, P Naud, et al.
Journal of Medical Screening|June 25, 2008
Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS studyS F Derchain, L O Sarian, P Naud, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Pageof 2